Core Viewpoint - The report from China Merchants Securities International downgrades the rating of Giant Bio (02367) from "Buy" to "Neutral" and reduces the target price by 45% from HKD 64 to HKD 35, citing multiple challenges including a series of reputation crises and a double-digit decline in its core brand, Kefu Mei, during the Double Eleven shopping festival [1] Group 1: Company Challenges - The company is facing significant challenges, including reputation issues and a decline in sales for its core brand during key promotional periods [1] - The investment logic for Giant Bio has shifted from growth to strategic adjustment, indicating a lack of clear catalysts for recovery [1] Group 2: Financial Projections - The firm has lowered its revenue forecasts for 2025-2027 by an average of 30% to reflect the latest guidance from management and a more cautious outlook for 2026 [1] - The sales expense ratio forecast has been increased from 36% to 38% to account for execution challenges during the adjustment phase [1] Group 3: Market Sentiment - The firm believes that current market consensus expectations may be overly optimistic, suggesting a need for a more cautious approach until signs of stabilization are clearer [1] - The target price adjustment is based on a reduction in the 2026 forecast price-to-earnings ratio from 21.5 times to 16 times [1]